Are drug costs for Lagebrio and Zocova Tablets covered by public funding?

If a patient with COVID-19 infection receives an outpatient prescription (including prescriptions at pharmacies) such as Lagebrio or Zocova Tablets (including prescriptions at pharmacies) after April 2024, the drug cost will be borne by public expenses. Not covered by
(Until the end of September 2023, all drug costs were covered by public expenditure, and from October 2023 to March 2024, partly covered by public expense.)
In addition, the procedure fee for prescribing the drug is not covered by public funding. (The same applies from May 8, 2023 to the end of March 2024.)

[Reference] Out-of-pocket expenses for the treatment of COVID-19 infection (October 2023 to March 2024)

• medical expenses's out-of-pocket ratio: 3,000 yen
• medical expenses's out-of-pocket ratio of 20%: 6,000 yen
• medical expenses's out-of-pocket ratio of 30%: 9,000 yen

Therapeutic agents for COVID-19 infections, such as Lagebrio and Zocova Tablets, are limited to those that can be prescribed respectively. For more information, please refer to "Can anyone prescribed therapeutic drugs if infected with COVID-19?"